Publications

  • Ε. Χαραλάμπους «An investigation on the sensitivity of Serratia liquefaciens (CP6) to bacteriophages CP6-D, CP6-E and CP6-F» Διπλωματική εργασία στα πλαίσια του BSc Γενετικής, 1999.
  • Ε. Χαραλάμπους « Gene Therapy in Breast cancer » Διπλωματική εργασία στα πλαίσια του MSc Ιατρικής Γενετικής και Ανοσολογίας, 2000.
  • Κ. Κυριάκου, Α. Χατζησάββας, Ε. Χαραλάμπους, : «Γενετική του καρκίνου του μαστού: η εμπειρία στην Κύπρο», Ανακοίνωση στο 9ο μετεκπαιδευτικό συνέδριο κλινικής ογκολογίας 2001. (Πρακτικά 9ου μετεκπαιδευτικού συνεδρίου κλινικής ογκολογίας 2001)
  • Charalambous : “K-ras mutations in colorectal cancer of Cypriot patients”. Ανακοίνωση στο Μarianna Lordos Cancer Seminar. Λάρνακα, Κύπρος, Φεβρουάριος 2002.
  • Hadjisavvas, E. Charalambous, A. Adamou, Ch. G. Christodoulou and K. Kyriacou, BRCA2 germline mutations in Cypriot patients with familial breast/ovarian cancer, Human Mutation, February 2003 issue (583), Mutation in brief (MIB).
  • Hadjisavvas, E. Charalambous, A. Adamou, S. L. Neuhausen, Ch. G. Christodoulou, K. Kyriacou, Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation, Cancer Genetics and Cytogenetics, vol. 151 (2004) p.p. 152–156
  • Ε. Χαραλάμπους «Διερεύνηση των μεταλλάξεων του B-RAF σε νεοπλάσματα Θυρεοειδούς» Διπλωματική εργασία στα πλαίσια του Μεταπτυχιακού «Ιατρική Ερευνητική μεθοδολογία», 2005
  • Mitsiades CS, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Charalambous E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Mitsiades N. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.J Clin Endocrinol Metab. 2006 Sep;91(9):3662-6.
  • Mitsiades CS, Kotoula V, Poulaki V, Charalambous E, Fanourakis G, Tseleni-Balafouta S, Mitsiades N. The Transcription Factor NF-B Is Constitutively Overactivated in Aggressive Human Thyroid Carcinomas: Therapeutic Implications. ENDO 2006, June 24-27, Boston, MA, Ρ2-360 (www.endo-society.org/educationevents/annual/ ).
  • Mitsiades CS, Negri J, Kotoula V, McMullan C, Charalambous E, Fanourakis G, Mitsiades N. Restoration of p53 Activity by the Synthetic Peptide p46 and the Small Molecule PRIMA-1 Induces Apoptosis in Thyroid Carcinoma Cell Lines: Therapeutic Implications. ENDO 2006, June 24-27, Boston, MA, Ρ2-351 (www.endo-society.org/educationevents/annual/ ).
  • Kotoula V, Koletsa T, Charalambous E, Pliakos I, Karayannopoulou G, Karkavelas G, Mitsiades CS, Mitsiades N. In situ detection of microRNAs146b, 221 and 222 in human carcinoma tissues reveals tumor-type specific expression patterns. AACR 2007 Annual Meeting, Los Angeles, CA, April 14 – 18, #1780 (www.aacr.org ).
  • Kotoula V, Charalambous E, Koletsa T, Pliakos I, Karkavelas G, Mitsiades CS, Mitsiades N. Distinct Patterns of Expression of microRNAs 146b, 221 and 222 in Human Thyroid Carcinomas: Clinical Implications. ENDO 2007, Toronto, Canada, June 2 – 5, P1-645 (http://www.endo-society.org/educationevents/annual/ )
  • Charalambous E, Kotoula V, Mitsiades CS, MItsiades N. Antitumor Effects Of The Tyrosine Kinase Inhibitor ZD6474 (Vandetanib) In Human Thyroid Carcinoma Cell Lines. Submitted for presentation at the 78th Annual Meeting of the American Thyroid Association (October 4 – 7, 2007)
  • Χαραλάμπους Ελπίδα, Κολέτσα Τριανταφυλλιά, Πλιάκος Ιωάννης, Γκουτζαμάνης Γεώργιος, Μητσιάδης Νικόλαος, Μητσιάδης Κωνσταντίνος, Καραγιαννοπούλου Γεωργία, Καρκαβέλας Γεώργιος, Κωτούλα Βασιλική In situ διερεύνηση των microRNAs 146b, 221 και 222 σε θυρεοειδικά καρκινώματα. 10ο Πανελλήνιο Συνέδριο της Ελληνικής Εταιρίας Χειρουργικής Ενδοκρινών Αδένων (Ε.Ε.Χ.Ε.Α.) Αθήνα 23-25 Νοεμβρίου 2007 #20. Βραβείο «Α. Ψάρρα»
  • Koletsa T, Kostopoulos I, Charalambous E, Christoforidou B, Nenopoulou E, Kotoula V. A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas. Neoplasia. 2008 Jul;10(7):687-96.
  • Charalambous, V. Kotoula, P. Hayden, D. W. McMillin, J. Negri, C. S. Mitsiades and N. Mitsiades. Anti-tumor effects of the tyrosine kinase inhibitors sunitinib (SU11248) and vandetanib (ZD6474) in human thyroid carcinoma cell lines. 33rd Annual Meeting of the European Thyroid Association (20-24 September 2008) P013 http://www.eurothyroid.com/
  • Kotoula, E. Charalambous, P. Hayden, E. Daskalaki, C.S. Mitsiades and N. Mitsiades. A transcriptional signature of thyroid carcinoma cell response to the tyrosine kinase inhibitors (TKIs) vandetanib and sunitinib: Identification of possible biomarkers of early clinical activity. (Endocrine Society Annual Meeting 2009, June 10-13, Washington, DC).
  • Charalambous, V. Kotoula, P. Hayden, D.W. McMillin, E. Daskalaki, C.S. Mitsiades and N. Mitsiades. Intermittent, pulsatile treatment of thyroid carcinoma cells with the tyrosine kinase inhibitors (TKIs) vandetanib and sunitinib has comparable activity to continuous drug exposure: Role of dual specificity phosphatase 6 (DUSP6/MKP3) and implications for design of future clinical trials of TKIs in aggressive thyroid cancer. (Endocrine Society Annual Meeting 2009, June 10-13, Washington, DC)
  • Charalambous, V. Kotoula, P. Hayden, E. Daskalaki, C.S. Mitsiades and N. Mitsiades. Combinations of tyrosine kinase inhibitors (TKIs) with conventional chemotherapeutics or diverse classes of targeted agents in human thyroid carcinoma cell lines: Lack of major synergistic activity in vitro and implications for design of future clinical trials of TKIs in aggressive thyroid cancer. (Endocrine Society Annual Meeting 2009, June 10-13, Washington, DC)
  • Ooi, V. Kotoula, E. Charalambous, E. Daskalaki, C.S. Mitsiades and N. Mitsiades. The antidiabetic biguanide metformin induces growth arrest in thyroid carcinoma cells in vitro. (Endocrine Society Annual Meeting 2009, June 10-13, Washington, DC)
  • Kotoula V, Charalambous E, Biesmans B, Malousi A, Vrettou E, Fountzilas G, Karkavelas G. Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics. PLoS One. 2009 Nov 4;4(11):e7746. doi: 10.1371/journal.pone.0007746.
  • Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O’Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res. 2009 Dec 1;15(23):7153-60. doi: 10.1158/1078-0432.CCR-09-1071.
  • Ε. Χαραλάμπους «Μελέτη μοριακών παραμέτρων στον καρκίνο του θυρεοειδούς για την αναγνώριση δεικτών πρόβλεψης ευαισθησίας σε στοχευμένη θεραπεία» Διδακτορική Διατριβή, στα πλαίσια του Ερευνητικού προγράμματος ΠΕΝΕΔ, Α.Π. 583/03, Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης, Ιατρική Σχολή, 2011
  • Helena Linardou, Paris A. Kosmidis, Vassiliki Kotoula, Vasilios Karavasilis, Anastasia G Eleftheraki, Georgios Lazaridis, Emily Daskalaki, Sotiris Lakis, Elpida Charalambous, Epaminontas Samantas, Dimitrios G. Pectasides, Dimitris Bafaloukos, George Fountzilas; Hellenic Cooperative Oncology Group (HeCOG), Evaluation of the prognostic/predictive role of tumor EGFR and KRAS mutations in Greek metastatic non-small cell lung cancer patients treated with first-line chemotherapy. ASCO 2013, #114402
  • Vassiliki Kotoula, Mattheos Bobos, George Kouvatseas, Christos Papadimitriou, Kyriaki Papadopoulou, Elpida Charalambous, Eleftheria Tsolaki, George Fountzilas. Genomic CNV testing on chromosome 17q genes reveals clinically relevant subtypes in breast cancer. AACR 2013 # 1918
  • Kamposioras K, Konstantara A, Kotoula V, Lakis S, Kouvatseas G, Akriviadis E, Vrettou E, Dionysopoulos D, Krikelis D, Papadopoulou K, Charalambous E, Chrisafi S, Konstantaras C, Fountzilas G. The prognostic significance of WNT pathway in surgically-treated colorectal cancer: β-catenin expression predicts for disease-free survival. Anticancer Res. 2013 Oct;33(10):4573-84.
  • Pentheroudakis G, Kotoula V, Fountzilas E, Kouvatseas G, Basdanis G, Xanthakis I, Makatsoris T, Charalambous E, Papamichael D, Samantas E, Papakostas P, Bafaloukos D, Razis E, Christodoulou C, Varthalitis I, Pavlidis N, Fountzilas G. A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG). BMC Cancer. 2014 Feb 20;14:111. doi: 10.1186/1471-2407-14-111.
  • Kotoula V, Papadopoulou K, Charalambous E, Zagouri F, Lakis S, Lymberopoulou A, Tsolaki E, Pentheroudakis G, Lilakos K, Pectasides D, Fountzilas G. Hellenic Cooperative Oncology Group (HeCOG). Routinelyapplicable, highly multiplexed triple negative breast cancer (TNBC) genotyping. AACR 2014, #3579.
  • Kotoula V, Bobos M, Alexopoulou Z, Papadimitriou C, Papadopoulou K, Charalambous E, Tsolaki E, Xepapadakis G, Nicolaou I, Papaspirou I, Aravantinos G, Christodoulou C, Efstratiou I, Gogas H, Fountzilas G. Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17. PLoS One. 2014 Aug 6;9(8):e103707. doi: 10.1371/journal.pone.0103707.
  • Pentheroudakis G, Kotteas EA, Kotoula V, Papadopoulou K, Charalambous E, Cervantes A, Ciuleanu T, Fountzilas G, Pavlidis N. Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group. Clin Exp Metastasis. 2014 Oct;31(7):761-9. doi: 10.1007/s10585-014-9666-1.
  • Pentheroudakis G, Kotoula V, Kouvatseas G, Charalambous E, Dionysopoulos D, Zagouri F, Koutras A, Papazisis K, Pectasides D, Samantas E, Dimopoulos MA, Papandreou CN, Fountzilas G. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer. Clin Breast Cancer. 2014 Oct;14(5):330-8. doi: 10.1016/j.clbc.2014.02.009.
  • Kotoula V, Lyberopoulou A, Papadopoulou K, Charalambous E, Alexopoulou Z, Gakou C, Lakis S, Tsolaki E, Lilakos K, Fountzilas G. Evaluation of two highly-multiplexed custom panels for massively parallel semiconductor sequencing on paraffin DNA. PLoS One. 2015 Jun 3;10(6):e0128818. doi: 10.1371/journal.pone.0128818.
  • Vassiliki Kotoula, Aggeliki Lyberopoulou, Kyriaki Papadopoulou, Elpida Charalambous, Sotiris Lakis, Zoi Alexopoulou, Eleftheria Tsolaki, Konstantinos Lilakos, George Fountzilas. Hellenic Cooperative Oncology Group (HeCOG). Evaluation of highly-multiplexed custom panels for targeted massively parallel semiconductor sequencing on paraffin DNA. AACR 2015 #4740
  • Papaxoinis G, Kotoula V, Alexopoulou Z, Kalogeras KT, Zagouri F, Timotheadou E, Gogas H, Pentheroudakis G, Christodoulou C, Koutras A, Bafaloukos D, Aravantinos G, Papakostas P, Charalambous E, Papadopoulou K, Varthalitis I, Efstratiou I, Zaramboukas T, Patsea H, Scopa CD, Skondra M, Kosmidis P, Pectasides D, Fountzilas G. Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study. PLoS One. 2015 Oct 9;10(10):e0140293. doi: 10.1371/journal.pone.0140293.
  • Helen Gogas, Vassiliki Kotoula, Zoi Alexopoulou, Christos Christodoulou, Ioannis Kostopoulos, Mattheos Bobos, Georgia Raptou, Elpida Charalambous, Eleftheria Tsolaki, Ioannis Xanthakis, George Pentheroudakis, Angelos Koutras, Dimitrios Bafaloukos, Pavlos Papakostas Gerasimos Aravantinos, Amanda Psyrri, Kalliopi Petraki, Konstantine T Kalogeras, George Fountzilas,Dimitrios Pectasides. Genomic parameters affecting the outcome of patients with advanced breast cancer treated with trastuzumab. San Antonio Breast Cancer Symposium 2015, #851195
  • Gogas H, Kotoula V, Alexopoulou Z, Christodoulou C, Kostopoulos I, Bobos M, Raptou G, Charalambous E, Tsolaki E, Xanthakis I, Pentheroudakis G, Koutras A, Bafaloukos D, Papakostas P, Aravantinos G, Psyrri A, Petraki K, Kalogeras KT, Pectasides D, Fountzilas G. MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer. J Transl Med. 2016 May 17;14(1):136. doi: 10.1186/s12967-016-0883-z.
  • Vassiliki Kotoula, Eleni Giannoulatou, Zoi Alexopoulou, Vasilios Karavasilis, Athanasios Kotsakis, Dimitrios Dionysopoulos, Christos Christodoulou, Eleftheria Tsolaki, Mattheos Bobos, Elpida Charalambous, George E. Pentheroudakis, Thomas Makatsoris, Sofia Chrisafi, Dimitrios G. Pectasides, Amanda Psyrri, Pavlos Papakostas, Evangelia Razis, Dimitris Bafaloukos, Vasileios Georgoulias, George Fountzilas. Tumor infiltrating lymphocytes and hydrophobic amino acid changes in HER2-positive metastatic breast cancer. 2016 ASCO Annual Meeting, #592
  • Pectasides D, Kotoula V, Papaxoinis G, Alexopoulou Z, Dervenis C, Samantas E, Papaparaskeva K, Charalambous E, Gkakou C, Agalianos C, Kalogeras KT, Pentheroudakis G, Fountzilas G. Expression Patterns of Growth and Survival Genes with Prognostic Implications in Advanced Pancreatic Cancer. Anticancer Res. 2016 Dec;36(12):6347-6356.
  • Gkotsi GM, Gasser J. (2016), Neuroscience in forensic psychiatry: from responsibility to dangerousness, International Journal of Law and Psychiatry, 46, May-June 2016, pp. 58-67
  • Γκότση Γ., (2016), Νευροεπιστήμες και ποινικό δίκαιο: υποσχέσεις και περιορισμοί σχετικά με την εκτίμηση της ικανότητας για καταλογισμό, Βιοηθικά Tόμος 2, Τεύχος 2
  • Gkotsi GM, Gasser J., “Critique of the use of neuroscience in forensic psychiatric assessments: The case of criminal responsibility”, L’Evolution Psychiatrique, 81(2), April–June 2016, pp. e25–e36
  • Gkotsi GM, (2014) Une «neuro-jurisprudence» émergente : quelques cas aux Etats Unis, in « Droit pénal et nouvelles technologies, (pp. 81-100), Editions L’Harmattan
  • Gkotsi GM; Moulin V; Gasser J. (2014) Les neurosciences au Tribunal, de la responsabilité à la dangerosité : nouvelles enjeux éthiques soulevés par la nouvelle loi française, L’Encéphale, 41(5), pp. 385-393
  • Gkotsi GM, Benaroyo L (2012) Neuroscience and the Treatment of Mentally Ill Criminal Offenders; Some Ethical Issues, Journal of Ethics in Mental Health, Vol 6, 2011/12, Supplement: Neuroethics
  • Gkotsi GM, Cabrera L, Andorno R (2012) Assessing the impact of the neuroscientific revolution on ethics and law, Bioethica Forum, 6(1), pp. 34-35
  • Vidalis T, Gkotsi GM, (2012) Neurolaw in the Greek Legal System, An Overview in International Neurolaw – A comparative analysis, ed. by Tade Matthias Spranger, Springer
  • Gkotsi GM, (5 Octobre 2012) Review of the Book Neuroimaging in Forensic Psychiatry: From the Clinic to the Courtroom by Simpson, J.R. (ed.): 2012, Chichester: Wiley-Blackwell. Short Litterature Notice by Roberto Andorno, in Medicine Health Care and Philosophy (2012) 15:469–473
  • Gkotsi GM, Gasser J, Moulin V (2016), Neuroscience in criminal courts: a case study, the role of experts – psychiatrists in International Journal of Law and Psychiatry (in press)
  • Marios Krokidis, Dionissios Papaioannou and Vassilios Nastopoulos. Crystallographic characterization of (Z)-tert-Butyl 2-(4-amino-9H-fluoren-9-ylidene)acetate, Acta Crystallographica, 2008, Section E, 64: 1978
  • Dimitra Hadjipavlou-Litina, George Magoulas, Marios Krokidis, Dionissios Papaioannou. Synthesis and evaluation of the antioxidant activity of acitretin analogs with amide bond(s) in the polyene spacer, European Journal of Medicinal Chemistry, 2010, 45: 298-310
  • Marios G. Krokidis, Ourania N. Kostopoulou, Dimitrios L. Kalpaxis, George P. Dinos. Dissecting the ribosomal inhibition mechanism of a new ketolide carrying an aryl-alkyl group at C-13 of its lactone-ring, International Journal of Antimicrobial Agents, 2010, 35: 235–239
  • George E. Magoulas, Stavros E. Bariamis, Constantinos M. Athanassopoulos, Anastasios Haskopoulos, Petros G. Dedes, Marios G. Krokidis, Nikos K. Karamanos, Dimitris Kletsas, Dionissios Papaioannou, George Maroulis. Syntheses, Antiproliferative Activity and Theoretical Characterization of Acitretin-Type Retinoids with Changes in the Lipophilic Part, European Journal of Medicinal Chemistry, 2011, 46: 721–737
  • Petros Mamos, Marios G. Krokidis, Athanassios Papadas, Panagiotis Karahalios, Agata L. Starosta, Daniel N. Wilson, Dimitrios L. Kalpaxis, and George P. Dinos. On the use of the antibiotic chloramphenicol to target polypeptide chain mimics to the ribosomal exit tunnel, Biochimie, 2013, 95: 1765-1772
  • Marios G. Krokidis, Viter Marquez, Daniel Wilson, Dimitrios Kalpaxis and George P. Dinos. Insights into the mode of novel fluoroketolides interact with wildtype and macrolide-resistant ribosomes, Antimicrobial Agents and Chemotherapy, 2014, 58: 472-480
  • Marios G. Krokidis, Antony Bougas, Maria Stavropoulou, Dimitrios L. Kalpaxis and George P. Dinos. The slow dissociation rate of K-1602 contributes to the enhanced inhibitory activity of this novel alkyl-aryl-bearing fluoroketolide, Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31(2):276-82
  • Chryssostomos Chatgilialoglu, Marios G. Krokidis, Kyriakos Papadopoulos and Michael A. Terzidis. Purine 5′,8-cyclo-2′-deoxynucleoside lesions: Recent developments, Radiation Physics and Chemistry, 2016, 128, 75-81
  • Michael A. Terzidis, Andreea Prisecaru, Zara Molphy, Niall Barron, Antonio Randazzo, Elise Dumont, Marios G. Krokidis, Andrew Kellett and Chryssostomos Chatgilialoglu. Radical-induced purine lesion formation is dependent on DNA helical topology, 2016, Free Radical Research, 50,S91-S101.

Leave a Reply